Rapamycin (sirolimus), longevity use

nutrient sensingautophagy mitophagyinflammation redox

Approved medicine for another condition in 9 of 9 markets tracked.

2 randomized trials (154 people, 13-48 weeks). Both found no effect on their main endpoint.

Doses studied: 6 mg intermittent.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (12)

T7 Moel 2025 Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results doi:10.18632/aging.206235
T7 Stanfield 2024 A Single-Center, Double-Blind, Randomized, Placebo-Controlled, Two-Arm Study to Evaluate the Safety and Efficacy of Once-Weekly Sirolimus (Rapamycin) on Muscle Strength and Endurance in Older Adults Following a 13-Week Exercise Program doi:10.1002/jcsm.70274
T5 El Jurdi 2025 Sirolimus use in allogeneic hematopoietic cell transplant recipients: assessing its senotherapeutic role in a high risk population doi:10.3389/fragi.2025.1673230
T3 Bitto 2016 Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice doi:10.7554/eLife.16351
TX BEYOND RAPAMYCIN - SELECTIVE INHIBITION… (2016) BEYOND RAPAMYCIN - SELECTIVE INHIBITION OF MTORC1 TO EXTEND HEALTHSPAN AND LIFESPAN doi:10.1093/geront/gnw162.2794
TX Blagosklonny 2011 Progeria, rapamycin and normal aging: recent breakthrough doi:10.18632/aging.100352
TX Kaeberlein 2016 EFFECTS OF TRANSIENT MID-LIFE RAPAMYCIN TREATMENT ON LIFESPAN AND HEALTHSPAN doi:10.1093/geront/gnw162.2793
TX Anisimov 2013 Multifaceted aging and rapamycin doi:10.18632/aging.100575
TX Lamming 2026 Bench to bedside: is rapamycin headed for the docTOR? doi:10.1007/s11357-026-02306-8
TX Blagosklonny 2019 Rapamycin for the aging skin doi:10.18632/aging.102664
TX Blagosklonny 2022 Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice doi:10.18632/aging.204354
TX Bjedov 2020 The Target of Rapamycin Signalling Pathway in Ageing and Lifespan Regulation doi:10.3390/genes11091043